
|Videos|August 3, 2021
Complementary use of mpMRI and genomic testing in prostate cancer
Author(s)Urology Times staff
Advertisement
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5










